Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Ablynx : Belgian biotech Ablynx scores big hit with blood disease drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 10:15am CEST

(Reuters) - Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion (£825 million).

Ablynx said its caplacizumab medicine met the primary and secondary goals in a late-stage trial testing the treatment in patients with acquired thrombotic thrombocytopenic purpura (aTTP).

This included a 74 percent relative reduction in the percentage of patients with aTTP-related death, a recurrence of aTTP or at least one major thromboembolic event during the study drug treatment period.

Shares in Ablynx jumped 25 percent in early trade on what Jefferies analysts described as near best-case results.

The brokerage assumes caplacizumab will launch in mid-2018 in Europe and the first half of 2019 in the United States and will generate worldwide peak sales of $400 million. Caplacizumab is wholly-owned by Ablynx, so sales should be highly profitable.

"These results strengthen our resolve to obtain marketing approval as quickly as possible so that caplacizumab rapidly becomes available to patients suffering from this severe disease for which there is currently no approved drug available," said Ablynx CEO Edwin Moses.

(Reporting by Ben Hirschler; Editing by Edmund Blair)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
07/10ACCELERON PHARMA : Appoints Robert K. Zeldin, M.D., Chief Medical Officer
AQ
07/06SANOFI : - CHMP recommends approval of Cablivi
AQ
06/30Sanofi, Advent finally shake hands on $2.2B European generics sale
AQ
06/29ABLYNX : `Rapidly evolving` biotech company to create 10 jobs at York Science Pa..
AQ
06/29SANOFI : CHMP Recommends Approval of Cablivi (Caplacizumab)
AQ
06/22SANOFI : completes its acquisition of Ablynx following the expiration of the Squ..
AQ
06/21SANOFI : completes $3.9bn acquisition of Ablynx
AQ
06/20SANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
06/19ABLYNX : Sanofi completes its acquitision of ablynx following the expiration of ..
GL
05/29ABLYNX : Crossing thresholds
CO
More news
News from SeekingAlpha
05/02YOUR DAILY PHARMA SCOOP : KPTI Data, Allergan Write-Off, Celgene Down On Delay 
04/30Ablynx completes enrollment in mid-stage study of ALX-0171 in RSV 
03/26Ablynx's vobarilizumab flunks mid-stage lupus study 
03/02Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV 
02/22Ablynx NV reports FY results 
Financials (€)
Sales 2018 94,0 M
EBIT 2018 -9,76 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 37,2x
Capi. / Sales 2019 19,8x
Capitalization 3 498 M
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert Freisen Chief Scientific Officer
Remi Vermeiren Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX117.28%0
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147